Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Issue Archive

Table of Contents

INSIDE BLOOD ADVANCES

REVIEW ARTICLES

SYSTEMATIC REVIEW

CLINICAL TRIALS AND OBSERVATIONS

T cell exhaustion and an immunosuppressive microenvironment is a hallmark of CTCL. Durvalumab combined with lenalidomide has the potential to enhance anti-tumor immunity in CTCL.

HEALTH SERVICES AND OUTCOMES

HEMATOPOIESIS AND STEM CELLS

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

RESEARCH LETTERS

LETTER TO THE EDITOR

ERRATUM

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals